ArticleAME case reports2025
Metastasis of nasopharyngeal carcinoma to the spleen: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Splenic metastasis from nasopharyngeal carcinoma (NPC) is exceptionally rare, accounting for only about 1% of all splenic metastases from solid tumors. Fewer than 30 cases have been documented worldwide. NPC is a common head and neck malignancy in certain regions, with a tendency to metastasize to regional lymph nodes in approximately 70% of cases, while distant metastases occur in about 30%. The spleen is an unusual site for secondary involvement, possibly due to its anatomical and immunological characteristics. Case Description: We report a 40-year-old male with a significant smoking history who initially presented with cervical lymphadenopathy and was diagnosed with Epstein-Barr virus-associated, poorly differentiated non-keratinizing NPC (T3N2M0). He received concurrent chemoradiotherapy, followed by several lines of systemic therapy and targeted radiotherapy for progressive bone and abdominal lymph node metastases. During follow-up, he developed intermittent left-sided abdominal discomfort. Positron emission tomography/computed tomography (PET/CT) and abdominal magnetic resonance imaging (MRI) demonstrated a new splenic lesion. Multidisciplinary tumor board review recommended laparoscopic splenectomy with distal pancreatectomy for both diagnostic and therapeutic purposes. The postoperative course was uneventful, and histopathology confirmed metastatic NPC. Despite surgery, subsequent surveillance revealed gastric metastasis, and the patient was placed on palliative systemic treatment. Conclusions: Although rare, splenic metastasis should be considered in NPC patients presenting with new abdominal symptoms or suspicious imaging findings during surveillance. Early detection through advanced imaging modalities such as PET/CT, MRI, and ultrasonography can facilitate timely intervention. Splenectomy remains a reasonable option in selected cases, offering diagnostic certainty, symptom relief, and prevention of potential complications such as splenic rupture or local invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.